Literature DB >> 1804000

Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans.

E W van Etten1, N E van de Rhee, K M van Kampen, I A Bakker-Woudenberg.   

Abstract

The effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans were studied. With respect to the extracellular growth of C. albicans, antifungal activity was measured in terms of MICs and minimal fungicidal concentrations as well as by determination of the concentration that effectively killed (greater than 99.9%) C. albicans in the absence or presence (amphotericin B only) of serum. Amphotericin B was highly active in terms of killing, even at an increased inoculum size. In the presence of serum, amphotericin B activity was substantially reduced. For fluconazole, activity was restricted to inhibition of fungal growth, even after the inoculum size was reduced. With respect to the intracellular growth of C. albicans, antifungal activity was measured by using monolayers of murine peritoneal macrophages infected with C. albicans and was measured in terms of inhibition of germ tube formation as well as effective killing (greater than 99%) of C. albicans. Amphotericin B was highly active against C. albicans. At an increased ratio of infection, amphotericin B activity was slightly reduced. Fluconazole had no antifungal activity. Neither a reduction in the ratio of infection nor exposure of C. albicans to fluconazole prior to macrophage ingestion resulted in activity against intracellular C. albicans by fluconazole. Previous exposure of C. albicans to amphotericin B resulted in increased intracellular activity of amphotericin B. The intracellular antifungal activity of the combination of fluconazole with amphotericin B was less than that of amphotericin B alone. Amphotericin B showed fungicidal activity against C. albicans growing both extracellularly and intracellularly, whereas fluconazole inhibited growth only of extracellular C. albicans. A slight antagonistic effect between fluconazole and amphotericin B was found with respect to intracellular as well as extracellular C. albicans.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1804000      PMCID: PMC245371          DOI: 10.1128/AAC.35.11.2275

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans.

Authors:  M J Humphrey; S Jevons; M H Tarbit
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

2.  The new generation of antifungal drugs.

Authors:  D A Stevens
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-12       Impact factor: 3.267

Review 3.  Overview of medically important antifungal azole derivatives.

Authors:  R A Fromtling
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

4.  Action of fluconazole (UK-49,858) in relation to other systemic antifungal azoles.

Authors:  C E Hughes; W H Beggs
Journal:  J Antimicrob Chemother       Date:  1987-02       Impact factor: 5.790

5.  Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo.

Authors:  T E Rogers; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

6.  Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice.

Authors:  P F Troke; R J Andrews; K W Brammer; M S Marriott; K Richardson
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

7.  Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits.

Authors:  J R Perfect; D V Savani; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

Review 8.  Treatment of systemic fungal infections: recent progress and current problems.

Authors:  T J Walsh; A Pizzo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

Review 9.  Azole antifungal agents: emphasis on new triazoles.

Authors:  M S Saag; W E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

10.  Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes.

Authors:  K Richardson; K W Brammer; M S Marriott; P F Troke
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

View more
  18 in total

Review 1.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  Influence of human serum on antifungal pharmacodynamics with Candida albicans.

Authors:  G G Zhanel; D G Saunders; D J Hoban; J A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

3.  Nonspecific effect of Mycograb on amphotericin B MIC.

Authors:  D L Richie; M A Ghannoum; N Isham; K V Thompson; N S Ryder
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

4.  Activity of liposomal amphotericin B with prolonged circulation in blood versus those of AmBisome and fungizone against intracellular Candida albicans in murine peritoneal macrophages.

Authors:  E W van Etten; W van Vianen; J Hak; I A Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

5.  Improved detection of Candida albicans by PCR in blood of neutropenic mice with systemic candidiasis.

Authors:  A J van Deventer; W H Goessens; A van Belkum; H J van Vliet; E W van Etten; H A Verbrugh
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

6.  Aerosolized amphotericin B-liposomes for treatment of systemic Candida infections in mice.

Authors:  B E Gilbert; P R Wyde; G Lopez-Berestein; S Z Wilson
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

7.  Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.

Authors:  A Ayestarán; R M López; J B Montoro; A Estíbalez; L Pou; A Julià; A López; B Pascual
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

8.  Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum.

Authors:  E Martin; F Maier; S Bhakdi
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

9.  Novel aspect of amphotericin B action: accumulation in human monocytes potentiates killing of phagocytosed Candida albicans.

Authors:  E Martin; A Stüben; A Görz; U Weller; S Bhakdi
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

Review 10.  Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics.

Authors:  R Janknegt; S de Marie; I A Bakker-Woudenberg; D J Crommelin
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.